We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

60 hedge funds and large institutions have $482M invested in UroGen Pharma in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 6

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

40% more funds holding

Funds holding: 43 → 60 (+17)

6% more capital invested

Capital invested by funds: $454M → $482M (+$28.4M)

2.03% more ownership

Funds ownership: 60.04% → 62.07% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
60
Holders Change
+17
Holders Change %
+39.53%
% of All Funds
1.37%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
23
Increased
21
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$26.4M
2
CCM
Consonance Capital Management
New York
+$19.9M
3
Citadel Advisors
Citadel Advisors
Florida
+$13.9M
4
BlackRock
BlackRock
New York
+$5.23M
5
WCM
Wildcat Capital Management
New York
+$4.06M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$20M
2
PAI
ProQuest Associates IV
Florida
-$17.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.18M
4
CS
Credit Suisse
Switzerland
-$4.53M
5
DP
DSAM Partners
United Kingdom
-$3.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
Man Group
26
Man Group
United Kingdom
$1.05M +$1.23M +21,132 New
CBA
27
Coastal Bridge Advisors
Connecticut
$957K – – –
MCM
28
McKinley Capital Management
Alaska
$957K +$1.06M +18,210 +1,798%
Wells Fargo
29
Wells Fargo
California
$939K +$1.04M +17,881 +1,806%
Swiss National Bank
30
Swiss National Bank
Switzerland
$856K +$1M +17,200 New
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$840K +$983K +16,885 New
Goldman Sachs
32
Goldman Sachs
New York
$755K -$1.72M -29,527 -66%
Two Sigma Investments
33
Two Sigma Investments
New York
$745K +$872K +14,976 New
Northern Trust
34
Northern Trust
Illinois
$677K +$791K +13,598 New
VF
35
Virtu Financial
New York
$671K +$340K +5,848 +77%
JMPWA
36
JP Morgan Private Wealth Advisors
California
$610K – – –
Deutsche Bank
37
Deutsche Bank
Germany
$601K -$1.02M -17,580 -59%
TCIM
38
TIAA CREF Investment Management
New York
$569K +$665K +11,425 New
Two Sigma Advisers
39
Two Sigma Advisers
New York
$508K +$594K +10,200 New
DCM
40
DAFNA Capital Management
California
$498K +$320K +5,500 +122%
AIM
41
ARK Investment Management
Florida
$470K -$237K -4,064 -30%
AIM
42
Assured Investment Management
New York
$377K +$441K +7,578 New
Geode Capital Management
43
Geode Capital Management
Massachusetts
$355K – – –
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$334K +$391K +6,711 New
CSS
45
Cubist Systematic Strategies
Connecticut
$333K +$390K +6,694 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$301K +$58.4K +1,004 +20%
ARTA
47
A.R.T. Advisors
New York
$273K +$320K +5,500 New
UBS Group
48
UBS Group
Switzerland
$272K +$107K +1,847 +51%
Jane Street
49
Jane Street
New York
$227K +$266K +4,563 New
Vanguard Group
50
Vanguard Group
Pennsylvania
$208K +$242K +4,163 New
1
2
3

URGN Hedge Fund Activity: Q2 2018 in Review

60 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2018, worth a combined $482M — up 6.3% from $454M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new URGN positions and 6 closed out — a net gain of 17 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $26.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $20M sold.

  • 60 institutional investors held UroGen Pharma (URGN) as of Q2 2018, up from 43 in Q1 2018.
  • Funds reported $482M of UroGen Pharma stock for Q2 2018, up 6.3% quarter-over-quarter.
  • 23 funds opened new UroGen Pharma positions in Q2 2018 and 6 closed out, a net change of +17 holders.
  • The largest UroGen Pharma buyer in Q2 2018 was Menora Mivtachim Holdings, an estimated $26.4M added.
  • The largest UroGen Pharma seller in Q2 2018 was EcoR1 Capital, an estimated $20M sold.

Based on aggregated 13F filings for Q2 2018.